Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane

被引:46
作者
Ronco, C [1 ]
Bowry, S
机构
[1] St Bortolo Hosp, Div Nephrol & Dialysis, I-36100 Vicenza, Italy
[2] Fresenius Med Care, Bad Homburg, Germany
关键词
high-flux dialysis; haemodiafiltration; polysulfone membrane; nanotechnology;
D O I
10.1177/039139880102401005
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Current haemodialysis therapy modalities such as haemodiafiltration enhance the removal of larger uraemic solutes from the blood of patients on end-stage renal disease. A number of clinical investigations have demonstrated the clinical benefits of such therapies in contributing towards better patient survival rates and an improved quality of life. A fundamental prerequisite to the application of convective treatment modalities is the availability of appropriate, technologically-advanced high-flux dialysis membranes that are able to eliminate larger uraemic substances with high efficiency but without causing an excessive leakage of useful proteins. A new membrane, Helixone(R), has been developed specifically to meet the present-day requirements of high-flux dialysis and haemodiafiltration therapies involving large substitution rates. The application of nanotechnology fabrication principles and procedures has enabled the development of a membrane having highly-defined inner, separating layer surface structures that offer minimal resistance to the removal of large molecular weight substances across the membrane; for the first time, pore size dimensions, pore size distribution and pore geometry, have been modulated and controlled at the nanoscale level for Helixone(R). This paper describes the characterisation of the essential structure- and permeation-related parameters of the new membrane using a number of physical analytical techniques.
引用
收藏
页码:726 / 735
页数:10
相关论文
共 20 条
[1]  
BERLAND Y, 1995, CONTRIB NEPHROL, V113, P45
[2]   Relationship of dialysis membrane and cause-specific mortality [J].
Bloembergen, WE ;
Hakim, RM ;
Stannard, DC ;
Held, PJ ;
Wolfe, RA ;
Agodoa, LYC ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (01) :1-10
[3]  
Cheung AK, 1997, SEMIN NEPHROL, V17, P196
[4]   Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis [J].
Clark, WR ;
Hamburger, RJ ;
Lysaght, MJ .
KIDNEY INTERNATIONAL, 1999, 56 (06) :2005-2015
[5]   Hemodiafiltration with online regeneration of the ultrafiltrate [J].
de Francisco, ALM ;
Ghezzi, PM ;
Brendolan, A ;
Fiorini, F ;
La Greca, G ;
Ronco, C ;
Arias, M ;
Gervasio, R ;
Tetta, C .
KIDNEY INTERNATIONAL, 2000, 58 :S66-S71
[6]   A NEW FORM OF AMYLOID PROTEIN ASSOCIATED WITH CHRONIC-HEMODIALYSIS WAS IDENTIFIED AS BETA-2-MICROGLOBULIN [J].
GEJYO, F ;
YAMADA, T ;
ODANI, S ;
NAKAGAWA, Y ;
ARAKAWA, M ;
KUNITOMO, T ;
KATAOKA, H ;
SUZUKI, M ;
HIRASAWA, Y ;
SHIRAHAMA, T ;
COHEN, AS ;
SCHMID, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 129 (03) :701-706
[7]  
Hörl WH, 2001, CONTRIB NEPHROL, V133, P28
[8]  
Hörl WH, 2000, J NEPHROL, V13, pS83
[9]   Principles and practice of hemofiltration and hemodiafiltration [J].
Ledebo, I .
ARTIFICIAL ORGANS, 1998, 22 (01) :20-25
[10]   Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival [J].
Leypoldt, JK ;
Cheung, AK ;
Carroll, CE ;
Stannard, DC ;
Pereira, BJG ;
Agodoa, LY ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) :349-355